Press Releases Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Market Closed - Nasdaq Other stock markets 21:00:00 08/05/2024 BST			5-day change	1st Jan Change
2.51 ^USD	+0.80%		+4.58%	-59.19%

05-01	Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-27	Sector Update: Health Care Stocks Ease Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Minerva Neurosciences: Q1 Earnings Snapshot	05-01	AQ
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates	05-01	AQ
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	02-27	AQ
Minerva Neurosciences: Q4 Earnings Snapshot	02-22	AQ
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates	02-22	AQ
Minerva Neurosciences: Q3 Earnings Snapshot	11-07	AQ
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates	11-07	AQ
Minerva Neurosciences : Aug 15, 2023	15/08/23	PU
Minerva Neurosciences: Q2 Earnings Snapshot	01/08/23	AQ
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates	01/08/23	AQ
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market	28/06/23	AQ
MINERVA NEUROSCIENCES, INC. : Other Events (form 8-K)	20/06/23	AQ
MINERVA NEUROSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	02/06/23	AQ
Minerva Neurosciences: Q1 Earnings Snapshot	15/05/23	AQ
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates	15/05/23	AQ
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia	10/05/23	AQ
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023	08/05/23	AQ
MINERVA NEUROSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	05/05/23	AQ
MINERVA NEUROSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	01/05/23	AQ
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia	01/05/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Press Releases

Filters